ECM
CRVS icon

Endurant Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Endurant Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,600
Closed -$282K – 95
2017
Q1 		$282K Buy
+13,600
New +$213K 0.09% 82

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Endurant Capital Management's CRVS Position: Q2 2017 in Review

Endurant Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2017, closing a stake of 13,600 shares — an estimated $282K sold.

Endurant Capital Management first reported a position in CRVS in Q1 2017 and held it in 1 quarter. The position peaked at $282K in Q1 2017. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

  • Endurant Capital Management reported no remaining Corvus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Endurant Capital Management sold 13,600 Corvus Pharmaceuticals shares in Q2 2017, an estimated $282K.
  • Endurant Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Endurant Capital Management's Corvus Pharmaceuticals position peaked at $282K in Q1 2017.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on Endurant Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.